Đang chuẩn bị liên kết để tải về tài liệu:
Adjuvant immunotherapy recommendations for stage III melanoma: Physician and nurse interviews

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Adjuvant immunotherapy is revolutionising care for patients with resected stage III and IV melanoma. However, immunotherapy may be associated with toxicity, making treatment decisions complicated. This study aimed to identify factors physicians and nurses considered regarding adjuvant immunotherapy for melanoma. |

TÀI LIỆU LIÊN QUAN

Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: A propensity score-matched analysis of real-world data

Adjuvant effect of IRES-based single-stranded RNA on melanoma immunotherapy

Adjuvant immunotherapy recommendations for stage III melanoma: Physician and nurse interviews

The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: A retrospective analysis

Lung erosion following adjuvant immunotherapy with pembrolizumab: A case report

Báo cáo y học: "Successful immunotherapy with matrix metalloproteinasederived peptides in adjuvant arthritis depends on the timing of peptide administration"

Báo cáo y học: "Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis"

The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40

Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: A case report

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: A systematic review and network meta-analysis